Pluripotent cells within embryonal carcinoma (EC) can differentiate in vivo or in vitro on treatment with specific agents. Differentiating EC cells express lower levels of stem cell-related genes, such as Cripto-1. We show that migration of human EC cells (NTERA/2 and NCCIT) can be reduced following treatment with the guidance molecule Netrin-1. Moreover, Netrin-1 treatment increased the levels of B-III tubulin, glial filament acidic protein, Nestin, and ;-aminobutyric acid and reduced the expressions of Cripto-1, Nanog, and Oct4 in EC cells. These Netrin-1-induced effects in the EC cells were mediated via binding of Netrin-1 to the Neogenin receptor and activation of SHP-2, resulting in increased levels of inactive phosphorylated c-src (Y527) . These results suggest that Netrin-1 can induce neuroectodermal-like differentiation of human EC cells by affecting c-src signaling via SHP-2 activation and regulation of Nanog, Oct4, and Cripto-1 expressions.
Introduction
Embryonal carcinoma (EC) is a germ-line tumor consisting of cells that can be induced to differentiate with agents, such as retinoic acid (1) . The malignant phenotype of EC cells can be reversed when injected into the mouse blastocyst and become incorporated into normally developing embryonic tissues (2) . Transcription factors, such as Oct4 and Nanog, which regulate self-renewal and pluripotency of embryonic stem (ES) cells (3) , are expressed in EC cells (4, 5) , suggesting that these transcription factors could also regulate pluripotency in EC cells. Cripto-1, an epidermal growth factor family member and target gene of Oct4 and Nanog, is expressed in ES cells and during the initial stages of development (6) . Cripto-1, also known as teratocarcinoma-derived growth factor-1 since first isolated from human NTERA/2 EC cells (7) , can induce cellular transformation in vitro and increase tumor incidence in vivo (6) . Interestingly, repression of Cripto-1 is associated with differentiation of EC cells toward a neuroectodermal lineage (7) . However, little information is known about how external factors, such as guidance molecules, may regulate the levels of Nanog and/or Oct4 and result in the differentiation of cancer cells with pluripotent characteristics.
Netrin-1, a secreted guidance molecule, can bind to specific cell surface receptors and regulate the development, functional differentiation, and trafficking of both neuronal and extraneuronal cells (8) . Netrin-1 can also regulate Cripto-1-induced cellular motility and allometric outgrowth of mouse mammary epithelial cells (9) . Recently, it has been shown that Netrin-1 can cause a reduction in the expression of Nanog and Cripto-1 and can increase expression of h-III tubulin in mouse ES cells, suggesting that Netrin-1 may affect early neuroectodermal differentiation in pluripotent cells (10) .
Here, we investigate the effect of Netrin-1 on human EC cells. Exogenous soluble Netrin-1 was able to reduce migration and induce increased levels of markers of early neuroectodermal differentiation in NTERA/2 and NCCIT EC cells. These responses to Netrin-1 were accompanied by increased levels of active phosphorylated SHP-2 (P-SHP-2) and inactive phosphorylated c-src
. Furthermore, Netrin-1-treated EC cells showed reduced levels of Cripto-1, Nanog, and Oct4. These results suggest that Netrin-1 can regulate differentiation in human EC cells.
Materials and Methods
Cell culture, recombinant proteins, migration, and proliferation assays. Human NTERA/2 and NCCIT EC cells were grown either in McCoy's 5A medium containing 15% fetal bovine serum (FBS; NTERA/2) or in DMEM containing 10% FBS (NCCIT) and cultured at 37jC in a humidified atmosphere of 5% CO 2 . Recombinant Netrin-1 protein was purchased from R&D Systems. Migration and cell proliferation assays were performed as previously described (11) . The experiments were performed in triplicate and repeated twice.
Western blot analysis. The human EC cells were seeded in 60-mm plates (6 Â 10 5 per plate), serum starved overnight, and then treated with medium alone (control) or with 50 ng/mL of exogenous soluble Netrin-1 for 30 min. For inhibitor studies, the cells were pretreated for 16 h with either medium alone (control) or anti-Neogenin blocking antibody (1 Ag/mL; Santa Cruz Biotechnology; ref. 12) and for 3 h with either medium alone (control) or SHP-2 inhibitor [50 Amol/L, 8-hydroxy-7-(6-sulfo-2-naphthylazo)-5-quinolinesulfonic acid disodium salt; Acros Organics] followed by stimulation with 50 ng/mL of exogenous soluble Netrin-1 for 30 min. Protein extraction and Western blot analysis were performed as described previously (11) . The following primary antibodies were used: mouse antiCripto-1 (1:500; Rockland); rabbit anti-Neogenin (1:1,000; Santa Cruz Biotechnology); rabbit anti-h-III tubulin (1:1,000; Abcam); mouse antiNestin (1:1,000; R&D Systems); rabbit anti-SHP-2, anti-P-SHP-2 (Y542)
, anti-P-c-src (Y416) , and anti-P-c-src (Y527) (1:1,000; Cell Signaling); mouse anti-glial filament acidic protein (GFAP; 1:1,000; Chemicon); mouse anti-src (1:500; Upstate-Millipore); and mouse anti-actin (1:20,000; Sigma). Densitometric analysis of Western blot results was performed with the NIH Image program. 4 Quantitative real-time PCR. EC cells were plated at a density of 6 Â 10 5 in 60-mm plates and serum starved for 24 h. The cells were then stimulated with exogenous soluble Netrin-1 at different concentrations for 30 min. Total RNA was isolated using RNeasy Mini kit (Qiagen) and quantitative real-time PCR (qRT-PCR) was performed on Stratagene MX3000P using Brilliant II SYBR Green QPCR master mix (Stratagene). The following primers were used: hGAPDH, 5 ¶-GAAGGTGAAGGTCG-GAGTC-3 ¶ ( forward) and 5 ¶-GAAGATGGTGATGGGATTTC-3 ¶ (reverse); hCripto-1, 5 ¶-CACGATGTGCGCAAAGAGA-3 ¶ ( forward) and 5 ¶-TGACC-GTGCCAGCATTTACA-3 ¶ (reverse); hNanog, 5 ¶-TGAACCTCAGCTACAAA-CAGGTG-3 ¶ ( forward) and 5 ¶-AACTGCATGCAGGACTGCAGAG-3 ¶ (reverse); hOct3/4, 5 ¶-CTTGCTGCAGAAGTGGGTGGAGGAA-3 ¶ ( forward) and 5 ¶-CTGCAGTGTGGGTTTCGGGCA-3 ¶ (reverse); and Nestin, 5 ¶-CAGCTGGCG-CACCTCAAGATG-3 ¶ ( forward) and 5 ¶-AGGGAAGTTGGGCTCAGGACTGG-3 ¶ (reverse). Relative quantification of Cripto-1 mRNA within the samples was performed using the C t method, as previously shown (11) .
Immunofluorescence. EC cells were treated for 48 to 72 h with either medium alone (control) or 50 ng/mL of exogenous soluble Netrin-1. Cells were incubated for 16 h at 4jC with the following primary antibodies: rabbit anti-g-aminobutyric acid (GABA; 1:1,000; Chemicon), rabbit anti-h-III tubulin (1:1,000), mouse anti-Nestin (1:1,000), and mouse anti-GFAP (1:1,000). Cells were processed for immunofluorescent staining as previously described (9).
Statistical analysis. The statistical significance of the various groups in the different experiments was calculated with the nonparametric MannWhitney U test. Statistical tests were two sided and data were considered statistically significant with P < 0.05.
Results and Discussion
Netrin-1 reduces migration and expression of Cripto-1, Nanog, and Oct4 in NTERA/2 and NCCIT human EC cells. Because the expression of Netrin-1 in human EC cells is unknown, we determined whether it would be expressed in NTERA/2 or NCCIT EC cells. In our study, we could not detect Netrin-1 protein by Western blot in either NTERA/2 or NCCIT EC cells (data not shown). However, the addition of 50 ng/mL of exogenous soluble Netrin-1 significantly reduced (P < 0.05) the migration of NTERA/2 and NCCIT EC cells compared with untreated control EC cells (Fig. 1A) . Netrin-1 did not significantly affect the 72-hour growth rates of either NTERA/2 or NCCIT EC cells (Fig. 1B) , suggesting that Netrin-1 did not reduce migration by inhibiting proliferation in the EC cells. A reduction in Cripto-1 levels can lead to lower migratory rates in Cripto-1-expressing cells (9, 11) ; therefore, we determined whether Netrin-1 treatment could affect Cripto-1 levels in NTERA/2 and NCCIT EC cells. Western blot and qRT-PCR analysis show a significant reduction in Cripto-1 protein and mRNA levels (P < 0.05) in Netrin-1-treated NTERA/2 and NCCIT EC cells compared with untreated controls (Fig. 1C) . Because Cripto-1 is a target gene of the stem cell-related transcription factors Oct4 and Nanog (13), we investigated whether Netrin-1 could affect the expressions of Oct4 and/or Nanog in NTERA/2 and NCCIT EC cells. Exogenous soluble Netrin-1 significantly reduced (P < 0.05) Oct4 and Nanog mRNA expression in NTERA/2 and NCCIT cells (Fig. 1D ). This agrees with similar observations that describe reduced Nanog and Cripto-1 levels in Netrin-1-treated mouse ES cells (10) .
NTERA/2 and NCCIT EC cells assume early neuronal-like characteristics when treated with Netrin-1. Exogenous agents, such as retinoic acid, can induce neuronal-like features in EC cells (1) . We investigated whether the effect of Netrin-1 on Cripto-1, Nanog, and Oct4 expression might be associated with differentiation of NTERA/2 and NCCIT EC cells. Western blot analysis shows that 12-day treatment of NTERA/2 or NCCIT EC cells with Figure 1 . Exogenous soluble Netrin-1 (50 ng/mL) reduced (*, P < 0.05) migration of NTERA/2 and NCCIT EC cells (A ) without affecting proliferation (B ) and significantly reduced the expressions of (C ) Cripto-1 (CR-1) protein and mRNA and (D ) Oct4 and Nanog mRNA (*, P < 0.05). HPF, high-power field; OD, absorbance.
50 ng/mL of exogenous soluble Netrin-1 increased expression of h-III tubulin, a common marker for early neuronal differentiation, in NTERA/2 (f2-fold) and NCCIT (f3.5-fold; Fig. 2A ) EC cells. Thus far, these results show that Netrin-1 can exert comparable effects in both NTERA/2 and NCCIT EC cells. Further analysis of Netrin-1-treated NTERA/2 cells shows increased levels of other markers of early neuronal development, such as Nestin (f2-fold) and GFAP (f3.5-fold; Fig. 2B ). Immunofluorescent staining confirmed the higher levels of h-III tubulin expressed in Netrin-1-treated NTERA/2 EC cells, which seemed to assume a more neuronal-like morphology with dendritic-or axonal-like cytoplasmic extensions (Fig. 2B) . Additional immunofluorescent staining showed increased expression of the neurotransmitter GABA in GFAP-positive Netrin-1-treated NTERA/2 EC cells compared with GFAP-negative untreated control cells (Fig. 2C) . We could not detect mRNA expression of either GATA4 or Brachyury, markers of endoderm and mesoderm differentiation, respectively, in Netrin-1-treated or untreated NTERA/2 or NCCIT EC cells (data not shown), suggesting that Netrin-1 may be more effective in regulating the expression of markers of neuroectodermal differentiation in human EC cells.
Netrin-1 activates SHP-2 and increases levels of inactive c-src in NTERA/2 EC cells. Netrin-1 can bind DCC/Neogenin and UNC5H family of receptors (14) . Western blot analysis showed expression of Neogenin (Fig. 3A) in NTERA/2 and NCCIT EC cells but not UNC5HA (data not shown), suggesting that Netrin-1 effects observed in NTERA/2 or NCCIT EC cells are most likely mediated via Neogenin. Changes in expression of either Neogenin or UNC5H in Netrin-1-treated and untreated NTERA/2 or NCCIT EC cells were not detected by Western blot analysis (data not shown). Previous studies have shown that several responses that are induced by Netrin-1 can be mediated via recruitment and activation of intracellular signaling molecules, such as the tyrosine phosphatase SHP-2 (15). In fact, treatment of NTERA/2 EC cells with 50 or 100 ng/mL of exogenous soluble Netrin-1 showed approximately 3-and 2.5-fold increase (P < 0.05), respectively, in the levels of active P-SHP-2 as determined by Western blot analysis (Fig. 3B) . A similar effect was observed in NCCIT EC cells (data not shown). Because SHP-2 is known to regulate many intracellular tyrosine kinases in different cell types (16), we determined whether this is also true in Netrin-1-treated EC cells. We could not detect differences in the activation of Akt, focal adhesion kinase (FAK), or mitogen-activated protein kinase in Netrin-1-treated and untreated NTERA/2 or NCCIT EC cells (data not shown). Members of the src family of tyrosine kinases are also affected by SHP-2 activity. Because Fyn and c-src activity have been implicated in Netrin-1 cellular effects (17) , it is possible that they might perform a role in the Netrin-1-induced effects in NTERA/2 and NCCIT EC cells. We therefore performed Western blot analysis to detect basal levels of Fyn and c-src in NTERA/2 and NCCIT to determine which of these tyrosine kinases could be affected by Netrin-1-induced SHP-2 activity. We could not detect activated Fyn in Netrin-1-treated or untreated NTERA/2 or NCCIT EC cells (data not shown). However, we did detect an increased ratio between inactive c-src [c-src (Y527) ] to active c-src [c-src (Y416) ] in Netrin-1-treated NTERA/2 and NCCIT EC cells (Fig. 3C and D) . The potential molecular interplay between Netrin-1, SHP-2, and c-src was further investigated in NTERA/2 cells. We found that the Netrin-1-induced effect on c-src was significantly reduced when NTERA/2 cells were pretreated with anti-Neogenin blocking antibody (1 Ag/mL) or with the SHP-2 inhibitor (50 Amol/L), alone or in combination (Fig. 3C and D) . Furthermore, when NTERA/2 EC cells were pretreated with the anti-Neogenin blocking antibody and with the SHP-2 inhibitor, Netrin-1 could no longer induce the expression of neuroectodermal markers, such as Nestin (Fig. 4A) , or repress the expression of Nanog, Oct4, and Cripto-1 (Fig. 4B) . These results suggest that exogenous soluble Netrin-1 may affect human EC cells by signaling via its receptor Neogenin and triggering the activation of SHP-2 resulting in reduced c-src activity.
We show that SHP-2 activation and reduction of active c-src is associated with reduced levels of Nanog, Oct4, and Cripto-1 and acquisition of neuroectodermal features in Netrin-1-treated human EC cells. Previous work has shown that activation of SHP-2 is associated with differentiation of ES cells (18) . Although other tyrosine kinases, such as Fyn and c-Yes, can play a role during the maintenance of pluripotency (19) , our data suggest that c-src may be more essential in the Netrin-1-induced effects observed in the human EC cells used in our study especially because Fyn, another mediator of Netrin-1 signaling (17), was not detected in the EC cells, nor was active FAK, a downstream component of Netrin-1-induced Fyn activity (20) . Taken together, these results show that Netrin-1 can reduce the aggressiveness of EC cells by influencing signaling pathways known to regulate pluripotency and affect the expression of stem cell-related transcription factors and target gene(s). These findings support the rationale for future investigation of the potential use of Netrin-1 for treatment of human EC.
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